Glycopeptide quadruples viability of stem cells in retina.
ST. MARYS, W.Va., May 2, 2016 -- Embry-onic stem cells treated with the antifreeze glycopeptide AAGP from ProtoKinetix and transplanted into retina tissue, an accepted model for the central nervous system, were 300 percent more viable than cells in the control group according to a study recently accepted for publication.
ProtoKinetix, Incorporated (OTCQB:PKTX) said that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix' AAGP was accepted by the Journal of Tissue Engineering and Regenerative Medicine for publication at a future date.
AAGP has been demonstrated to significantly improve the viable yield of stem cells transplanted in retinal tissue at the University of British Columbia under the guidance of Dr. Kevin Gregory-Evans.
He believes that AAGP works by inhibiting toxic signaling from surrounding necrotic (dead) tissue, which usually results from an inadequate local blood supply.
Necrotic tissue contains dead cells and debris that are a consequence of the fragmentation of dying cells.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Advanced Stem Cell Technology|
|Publication:||Stem Cell Business News|
|Date:||May 16, 2016|
|Previous Article:||European researchers to use Wafergen Single-Cell Systems.|
|Next Article:||Companies to collaborate via licensing agreement.|